Statistics from Altmetric.com
Nodulosis, arthropathy and osteolysis (NAO) syndrome is a rare autosomal recessive multicenteric osteolysis.1,2 Few therapeutic studies have proved the efficacy of pamidronate in children with genetic osteoporotic syndrome such as osteogensis imperfecta.3,4
Therefore, we conducted an uncontrolled prospective study to assess the effect of cyclic intravenous pamidronate treatment on the clinical course of NAO syndrome in children and its effect on bone mineral density.
Seven children with NAO syndrome aged 5–14 years were treated with intravenous pamidronate between June 2003 and July 2004. The treatment was given after informed consent was obtained from the parents.
Pamidronate was diluted in 250 ml of isotonic saline and infused …